Copper and gold producer Freeport-McMoRan serves an example of a dull but cheap stock that is finding investor favor again.
Mydecine Innovations Group -- formerly known as NewLeaf -- signed an agreement with the University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences.
Tivity Health's big price drop serves as an example of the thought process an investor must go through when a holding takes an unexpected hit.
Esperion Therapeutics, Agenus Inc. and Baudax Bio could see coming events trigger positive reactions in their shares.
Jana Partners indicates its plans to nominate a few director candidates to the restaurant operator's board.
The antibiotics maker recently received a significant federal contract that could help give its shares the juice they need to climb next year.
The trio involves unicorns, the FAANG stocks and blockchain.
The oncology company has had a strong run and all the technical signals indicate the move higher isn't over.
Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.
Assessing Aurora and its peers, strictly on the numbers.